Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
Daily Maverick on MSN1d
New chronic kidney disease treatments show promise, but are expensive and inaccessibleWhile the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...
MedPage Today on MSN4d
Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 InhibitorsUse of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...
Surendra Kumar Sahoo was just 27 years old when he discovered that he was suffering from end-stage renal disease, which meant ...
Chronic kidney disease can be a silent killer; thus, we need to know about the causes and symptoms of CKD in advance for ...
Research shows multiple factors drive CKD risk in lupus nephritis, including nephritic flares, baseline hypertension, renal ...
Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...
The impact of chronic kidney disease (CKD) keeps escalating around the world, and this burden is projected to rise with ...
Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and ...
In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.
Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback